title: Outcomes of Intra- and Extraocular Retinoblastomas from a Single Institute in South India.
abstract: OBJECTIVE
  To report treatment outcomes of intra- and extraocular retinoblastomas seen at Aravind Eye Hospital, Coimbatore, South India.
  
  
  METHODS
  Retrospective case series from January 2006 to December 2011 involving 106 babies. Clinical records were reviewed and data collected on presenting signs, gender, age, family history, ocular findings and treatment outcomes. All eyes were classified using the International Retinoblastoma Classification.
  
  
  RESULTS
  The mean follow up was 35.4 months (range 1-75 months, SD 20.2, median 33 months). The mean age of presentation was 20.8 months (range 5 days to 120 months). There were 68 unilateral and 38 bilateral cases. Globe salvage rates were 100% for group A (11 eyes), B (16 eyes) and C (2 eyes). For group D, eye salvage rate was 29.5% (10/34 eyes). Survival rate of orbital retinoblastoma in our study was 55.5% (5/9 cases) at a mean follow up of 33.6 months. The overall patient survival rate was 89.6% with 11 deaths (10.4%). The commonest cause of death (7/11) was distant metastasis due to refusal to take initial treatment.
  
  
  CONCLUSIONS
  Greater improvement in patient survival can be achieved not only by early treatment of intraocular disease but also to convince patients to accept treatments including enucleation in this part of the world.
authors.affiliation: a Department of Pediatric Retina & Ocular Oncology , Aravind Eye Hospital & Postgraduate Institute of Ophthalmology , Coimbatore , Tamilnadu , India.
authors.forename: Parag K
authors.initials: PK
authors.lastname: Shah
authors.forename: Venkatapathy
authors.initials: V
authors.lastname: Narendran
authors.forename: Narendran
authors.initials: N
authors.lastname: Kalpana
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016190:Carboplatin / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D003906:Developing Countries; D005047:Etoposide / Q000627:therapeutic use; D015353:Eye Enucleation; D005260:Female; D006801:Humans; D007194:India; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D017063:Outcome Assessment, Health Care; D061766:Proton Therapy; D019572:Retinal Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D012175:Retinoblastoma / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D012189:Retrospective Studies; D015996:Survival Rate; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D014750:Vincristine; D005047:Etoposide; D016190:Carboplatin
keywords: Developing country; outcomes; retinoblastoma